The use of recombinant granulocyte-colony stimulating factors (G-CSF’s) has significantly reduced the risk of febrile neutropenia associated with myelosuppressive chemotherapy. Recommendations published by the European Organisation for Research and Treatment of Cancer (EORTC) provide guidance on the use of G-CSF’s in European clinical practice. During the EHA 2015 Congress, a satellite symposium entitled: ‘Contemporary therapeutic strategies in B-cell lymphomas’ was organized by PriME Oncology and supported by Teva Pharma. One of the main topics discussed during this symposium was the implication of the latest EORTC recommendations in clinical practice. In his lecture, Dr. Matti Aapro, leading author of the EORTC guidelines, elaborated on these recommendations and on reducing the incidence of febrile neutropenia by improving the usage of G-CSF’s. A summary is given below.
(BELG J HEMATOL 2015;6(3):105–7)